{"transactions":[{"id":2387339,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-02-18T00:08:46.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":10.58,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-011033","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919122011033/doc4.xml","form_type":"4"}},{"id":2465061,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":195163,"derivative":{"exercise_price":12.85,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":882},"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2465060,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":24853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests as to 25% of the total shares monthly beginning on September 24, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":74575,"derivative":{"exercise_price":12.85,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":24853},"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2465059,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":3016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":1307,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":3016},"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2465058,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":28751,"price":13,"value":373763.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2465057,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":25735,"price":12.85,"value":330694.75,"ownership":{"direct":true},"balance_after":29195,"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2465056,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-12-17T22:20:12.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":3016,"price":1.89,"value":5700.24,"ownership":{"direct":true},"balance_after":3460,"source":{"system":"sec-edgar","filing":"0001209191-21-070352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121070352/doc4.xml","form_type":"4"}},{"id":2504243,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-11-18T23:42:21.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":28751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested as to 25% of the total shares monthly beginning on July 27, 2020, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date."}],"balance_after":196045,"derivative":{"exercise_price":12.85,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":28751},"source":{"system":"sec-edgar","filing":"0001209191-21-065616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121065616/doc4.xml","form_type":"4"}},{"id":2504242,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-11-18T23:42:21.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":400,"price":16.425,"value":6570.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.41 to $16.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-21-065616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121065616/doc4.xml","form_type":"4"}},{"id":2504241,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-11-18T23:42:21.000Z","date":"2021-11-16","kind":"sale","acquired":false,"shares":28351,"price":15.8711,"value":449961.5561,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.41 to $16.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":844,"source":{"system":"sec-edgar","filing":"0001209191-21-065616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121065616/doc4.xml","form_type":"4"}},{"id":2504240,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-11-18T23:42:21.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":28751,"price":12.85,"value":369450.35,"ownership":{"direct":true},"balance_after":29195,"source":{"system":"sec-edgar","filing":"0001209191-21-065616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121065616/doc4.xml","form_type":"4"}},{"id":2626900,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-07-22T22:14:26.000Z","date":"2021-07-20","kind":"grant","acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":85000,"derivative":{"exercise_price":31.23,"expiration_date":"2031-07-19","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001209191-21-047842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121047842/doc4.xml","form_type":"4"}},{"id":2734204,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-30T22:22:06.000Z","date":"2021-04-29","kind":"exercise","acquired":false,"shares":3223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested."}],"balance_after":4323,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":3223},"source":{"system":"sec-edgar","filing":"0001209191-21-029351","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121029351/doc4.xml","form_type":"4"}},{"id":2734203,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-30T22:22:06.000Z","date":"2021-04-29","kind":"sale","acquired":false,"shares":3223,"price":40.2896,"value":129853.3808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $41.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-21-029351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121029351/doc4.xml","form_type":"4"}},{"id":2734202,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-30T22:22:06.000Z","date":"2021-04-29","kind":"exercise","acquired":true,"shares":3223,"price":1.89,"value":6091.47,"ownership":{"direct":true},"balance_after":3667,"source":{"system":"sec-edgar","filing":"0001209191-21-029351","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121029351/doc4.xml","form_type":"4"}},{"id":2748218,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-15T23:11:38.000Z","date":"2021-04-08","kind":"exercise","acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":7546,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001209191-21-026873","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026873/doc4.xml","form_type":"4"}},{"id":2748217,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T23:11:38.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":100,"price":40,"value":4000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-21-026873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026873/doc4.xml","form_type":"4"}},{"id":2748216,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-15T23:11:38.000Z","date":"2021-04-08","kind":"exercise","acquired":true,"shares":100,"price":1.89,"value":189.0,"ownership":{"direct":true},"balance_after":544,"source":{"system":"sec-edgar","filing":"0001209191-21-026873","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026873/doc4.xml","form_type":"4"}},{"id":2751806,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-04-09T21:52:28.000Z","date":"2021-04-07","kind":"exercise","acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option is fully vested."}],"balance_after":7646,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-26","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001209191-21-026292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026292/doc4.xml","form_type":"4"}},{"id":2751805,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-09T21:52:28.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":1000,"price":40.043,"value":40043.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein."}],"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-21-026292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026292/doc4.xml","form_type":"4"}},{"id":2751804,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2021-04-09T21:52:28.000Z","date":"2021-04-07","kind":"exercise","acquired":true,"shares":1000,"price":1.89,"value":1890.0,"ownership":{"direct":true},"balance_after":1444,"source":{"system":"sec-edgar","filing":"0001209191-21-026292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919121026292/doc4.xml","form_type":"4"}},{"id":3020547,"issuer":{"id":5561,"kind":"organization","name":"Prelude Therapeutics Inc"},"owners":[{"id":130254,"kind":"person","name":"Morosini Deborah","position":1,"cik":"0001824625","reported_name":"Morosini Deborah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief of Clinical Affairs"}}],"security":"Common Stock","published_at":"2020-09-30T00:08:35.000Z","date":"2020-09-29","kind":"purchase","acquired":true,"shares":444,"price":19,"value":8436.0,"ownership":{"direct":true},"balance_after":444,"source":{"system":"sec-edgar","filing":"0001209191-20-052402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678660/000120919120052402/doc4.xml","form_type":"4"}}]}